Compare MATW & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATW | ABUS |
|---|---|---|
| Founded | 1850 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 827.2M | 888.5M |
| IPO Year | 1994 | N/A |
| Metric | MATW | ABUS |
|---|---|---|
| Price | $26.58 | $4.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 223.2K | ★ 1.6M |
| Earning Date | 02-03-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,497,689,000.00 | $14,606,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $0.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $18.50 | $2.71 |
| 52 Week High | $30.96 | $5.10 |
| Indicator | MATW | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 37.37 |
| Support Level | $26.23 | $3.99 |
| Resistance Level | $28.86 | $4.33 |
| Average True Range (ATR) | 1.08 | 0.23 |
| MACD | -0.21 | -0.07 |
| Stochastic Oscillator | 9.02 | 29.66 |
Matthews International Corp is a provider of memorialization products, industrial technologies and brand solutions. The company's segments are Memorialization, Industrial Technologies and Brand Solutions. The memorialization offerings include bronze and granite memorials, caskets, and cremation-related products and equipment for cemeteries and funeral homes. Its Industrial Technologies segment designs, manufactures, services, and sells custom energy storage systems and product identification and warehouse automation solutions. The Brand Solutions segment provides brand management, pre-media, printing plates and cylinders, imaging, digital asset management, merchandising displays, and marketing and design services. The majority of revenue is generated by Memorialization.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.